News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Marinus Pharmaceuticals
< Previous
1
2
3
Next >
Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
August 17, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 11, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder
July 31, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023
July 27, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 13, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus
June 21, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 02, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder
May 26, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
May 17, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
May 11, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 09, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
May 03, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
April 27, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors
April 18, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
March 22, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 06, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023
February 13, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
February 07, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors
January 30, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update
January 05, 2023
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 09, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting
November 30, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China
November 17, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering
November 07, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close